Lupus & antiphospholipid syndrome
Anifrolumab treatment improves patient-reported quality of life and decreases disease activity and corticosteroid use in patients with systemic lupus erythematosus: A qualitative study in Denmark
Study context
- Population
- Systemic lupus erythematosus (SLE) patients at Aarhus University Hospital who had received at least three infusions of Anifrolumab, DenmarkIn-depth interviews (IDIs) 14
- Comparison
- Before vs after Anifrolumab treatment
- Outcome
- Patient-reported symptoms and impacts on daily life before and after Anifrolumab
Methodological detailssemi-structured in-depth interviews, clinical chart review of EMR data, single-centre, Treatment days range: 62-474
- Semi-structured in-depth interviews
- Clinical chart review of EMR data
- Single-centre
- Treatment days range: 62-474
Main finding
As reported in the abstract
- 23 symptoms spontaneously reported before treatment; most common: fatigue, joint pain, sun sensitivity, joint stiffness, skin rashes, hair loss
- Most symptoms improved, and none worsened during treatment
- Improvements reported in all aspects of daily-life impact after treatment, but patients were still impacted
Further findings
Disease activity and corticosteroid use (EMR data, baseline, 3 and 6 months)
- Fall in disease activity after treatment initiation with a concomitant reduction in corticosteroid use
Original publication
Anifrolumab treatment improves patient-reported quality of life and decreases disease activity and corticosteroid use in patients with systemic lupus erythematosus: A qualitative study in Denmark. Lupus. Published 20 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →